Introduction {#s1}
============

Sepsis is a common yet complex disorder that remains one of the major causes of death among patients admitted to intensive care units (ICUs) ([@B22]; [@B49]). Septic shock, a severe subset of sepsis, represents a lethal yet intractable condition for ICU patients ([@B49]). The mortality rate shows significant increase after identification of septic shock, from 40% to 80% due to the untenable hemodynamic status and persistent low blood perfusion ([@B14]). Administration of norepinephrine is the first-line choice and an effective treatment for improving survival of septic shock patients ([@B40]). Furthermore other vasopressor medications, such as epinephrine, dopamine, and vasopressin and its analogs, also showed noteworthy benefits in ameliorating vascular resistance, achieving target mean arterial pressure (MAP) levels, and further maintaining efficient perfusion in tissues and crucial organs during septic shock ([@B53]).

However, patients with septic shock are prone to become insensitive to catecholamines, and even develop vasopressin deficiency ([@B43]). Meanwhile, growing evidences have shown that catecholamine associated adverse effects might be unavoidable by exclusively using catecholamines, including myocardial ischemia and tachycardia, which also poses a great threat to the prognosis of septic shock patients ([@B11]; [@B29]; [@B47]; [@B53]). Given that, several studies have demonstrated that combined administration of vasopressin or its analogs with catecholamines not only reduced the use of catecholamines, but also potentially attenuated catecholamine associated adverse effects ([@B10]; [@B17]). Thus, administration of vasopressin is recommended by recently issued Surviving Sepsis Guidelines to get the target MAP level, along with benefit of reducing NE dosage ([@B40]). Likewise, analogs of vasopressin, including terlipressin and selepressin, were reportedly beneficial for improving hemodynamic status, attenuating sepsis related vasodilatation and tissue edema, which were largely attributed to its selective stimulation of V~1~ receptors ([@B39]; [@B25]). Recently, results from two large randomized controlled trials (RCTs) were published and aroused the usage and effects of vasopressin or its analogs on the prognosis of septic shock patients ([@B30]; [@B26]). Of note, several well-designed systematic review and meta-analyses have evaluated the effects and safety of vasopressin or its analogs on the occurrence of adverse effects and short-term mortality, while the conclusions of those studies were divergent from each other ([@B48]; [@B4]; [@B32]; [@B24]; [@B36]). This might be due to disparate inclusion criteria and methodologic selection.

Therefore, we plan to conduct an updated systematic review and meta-analysis of RCTs to test the clinical efficiency of vasopressin or its analogs versus catecholamines alone on patients-centered outcomes during septic shock. Furthermore, we aim to explore if selective V~1~ receptor agonists (terlipressin, selepressin) show beneficial effects on clinical outcomes of septic shock patients.

Materials and Methods {#s2}
=====================

The current systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statements ([@B33]) (see [**Figure 1**](#f1){ref-type="fig"}).

![Flowchart for selection process.](fphar-11-00563-g001){#f1}

Eligibility Criteria and Outcome Measurement {#s2_1}
--------------------------------------------

RCTs comparing the use of vasopressin or its analogs (e.g. terlipressin, selepressin) with catecholamines alone (e.g. norepinephrine, dopamine) or placebo among adult patients with septic shock were included in the current study.

The primary endpoint was 28-day or 30-day mortality, which was preferentially reported by majority of included trials. In case of unreported 28-day or 30-day mortality, we contacted the authors for inquiring the original data or considered the closest available mortality data. Secondary outcomes were listed as follows: total adverse events, arrhythmia, acute myocardial infarction (AMI) and cardiac arrest, acute mesenteric ischemia, digital ischemia, ICU length of stay, hospital length of stay and duration of mechanical ventilation. For studies reported length of stay in median and interquartile range, we converted those data into mean and standard deviation, respectively, by using algorithm provided by statisticians.

Literature Search {#s2_2}
-----------------

A systematic search was conducted by applying multiple online databases, including Cochrane Library, EMBASE, and PubMed. Relevant studies up to 30 Oct, 2019 were reviewed irrespective of languages and publication types. We conceived search strategies that involved following Medical Subject Heading (MeSH) terms: "Sepsis," "Vasopressins," "Arginine Vasopressin," "Deamino Arginine Vasopressin," "Lypressin," "Felypressin," "Ornipressin," and "terlipressin." Detailed search strategies were summarized in [**Supplemental File 1**](#SM11){ref-type="supplementary-material"}. Besides, unpublished trials and conference abstracts were hand-searched by the authors to obtain additional studies. We also identified references through screening the reference lists of eligible reviews and trial registries.

Study Selection and Data Collection {#s2_3}
-----------------------------------

Two reviewers independently screened the titles and abstracts of relevant studies for enrolling eligible trials. If the abstract of a potentially eligible trial failed to provide sufficient information, the full paper was subsequently obtained to determine its eligibility. In both inclusion and exclusion processes, divergent opinions between the two authors were resolved by discussion. Otherwise, a consulting group that consisted of several experts was involved in when a consensus could not be reached.

Independently, two reviewers extracted data from included studies with a predesigned sheet. The primary and secondary outcomes were obtained across all eligible trials. In addition, detailed information about studies and participants' characteristics were recorded accordingly, including year of publication, first author, study design, total number of enrollments, type of intervention, demographic characteristics, clinical settings and complications. Similarly, the inconsistency of extracted data and disagreement were resolved by discussion.

Assessment of Risk of Bias {#s2_4}
--------------------------

The methodological quality of all included studies was assessed by using the Jadad scoring system, which was comprised of three dimensions (randomization, double-blinding as well as withdrawals and dropouts). Each trial was assigned a score of 0 to 5, a study with score higher than 3 indicated high quality and low risk of bias, or else, revealing high risk of bias.

Data Synthesis and Analysis {#s2_5}
---------------------------

We applied risk ratios (RRs) for dichotomous outcomes, while mean differences (MDs) were used for pooling continuous data. The pooled results were calculated with 95% confidence intervals (CIs). Methodological heterogeneity of each outcome was measured by using both χ^2^ test and I^2^ statistics. In either case, I^2^ \> 50% or P value \< 0.10 (χ^2^ test) was regard as significant heterogeneity. We applied random effects model combined with Mantel-Haenszel method for certain outcomes when statistical heterogeneity existed, or else, fixed effects model was used. A two-sided P value \< 0.05 was deemed as statistically significance. To measure publication bias across studies, the funnel plot of the primary endpoint was constructed and visually inspected by authors. Additionally, we performed Harbord and Peter tests to further evaluate the publication bias.

Subgroup analysis combined with sensitivity analysis were performed to test the robustness and consistency of our primary endpoint, as well as finding potential influencing factors. We stratified all included RCTs by administration of vasoactive agents (vasopressin or it's analogs), clinical settings, outcome report, risk of bias, as well as publication types (full text or abstract).

All statistical analyses were performed using R software (version 3.6.1).

Evaluation of the Quality of Evidence {#s2_6}
-------------------------------------

The quality of evidence of each outcome was evaluated in line with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria ([@B16]). This procedure was conducted with GRADE Pro software 3.6 (McMaster University 2014, Hamilton, Canada).

Results {#s3}
=======

Trial Selection Processes and Characteristics of Included Studies {#s3_1}
-----------------------------------------------------------------

The current meta-analysis identified 2,563 relevant citations through searching online databases. After removing duplicates and subsequent screening of titles and abstracts, the full-text articles of 41 trials were reviewed, and 23 RCTs finally met the eligibility criteria (see [**Figure 1**](#f1){ref-type="fig"}).

Twenty-three RCTs with 4,225 septic shock patients were enrolled in the systematic review and meta-analysis ([@B2]; [@B27]; [@B34]; [@B41]; [@B1]; [@B35]; [@B18]; [@B50]; [@B13]; [@B23]; [@B37]; [@B55]; [@B5]; [@B9]; [@B15]; [@B54]; [@B6]; [@B7]; [@B8]; [@B38]; [@B42]; [@B30]; [@B26]). The majority of enrolled trials were designed as single-center studies, while seven of them were multicenter studies. The administration of vasopressin was applied by 10 trials, and another 11 RCTs using terlipressin as the intervention, whereas selepressin was studied in two trials. Among them, six studies were published in conference abstract ([@B1]; [@B37]; [@B55]; [@B9]; [@B6]; [@B38]). The detailed characteristics of all included RCTs were presented in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of included randomized clinical trials.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                        Design          No. of patients   Clinical settings                      Intervention                                               Outcome measurement      Jadad score                                         
  -------------------------------------------- --------------- ----------------- -------------------------------------- ---------------------------------------------------------- ------------------------ --------------------------------------------------- ---
  [@B1]^\*^                                    Single center   24                Cirrhotic patients with septic shock   Terlipressin                                               Alpha-adrenergic drugs   Hospital mortality ICU mortality                    1

  [@B2]                                        Single center   20                Septic shock                           Terlipressin                                               NE                       Hospital mortality                                  2

  [@B5]                                        Single center   30                Septic shock                           Vasopressin plus NE                                        NE                       28-day mortality ICU mortality                      4

  [@B6]                                        NA              250               Cancer patients with septic shock      Vasopressin                                                NE                       28-day mortality 90-day mortality                   3

  [@B7]                                        Single center   57                Septic shock patients with ARDS        Terlipressin plus NE                                       NE                       28-day mortality                                    3

  [@B8]                                        Single center   84                Liver cirrhosis with septic shock      Terlipressin                                               NE                       28-day mortality 48-h mortality                     4

  [@B9]^\*^                                    Single center   82                Septic shock                           Vasopressin plus NE                                        NE                       28-day mortality                                    1

  [@B13]                                       Single center   30                Septic shock                           Vasopressin plus NE                                        NE                       28-day mortality                                    4

  [@B15]                                       Multicenter     409               Septic shock                           Vasopressin                                                NE                       28-day mortality Hospital mortality ICU mortality   5

  [@B18]                                       Multicenter     139               Septic shock                           Pituitrin                                                  Dopamine or NE           28-day mortality                                    1

  [@B23]                                       Single center   32                Septic shock patients with ARDS        Terlipressin                                               Dopamine                 28-day mortality                                    2

  [@B26]                                       Multicenter     828               Septic shock                           Selepressin                                                Placebo                  30-day mortality 180-day mortality                  5

  [@B27]                                       Multicenter     23                Septic shock                           AVP                                                        NE                       ICU mortality                                       3

  [@B30]                                       Multicenter     526               Septic shock                           Terlipressin                                               NE                       28-day mortality                                    5

  [@B34] [^a^](#fnT1_1){ref-type="table-fn"}   Single center   59                Septic shock                           Terlipressin plus NE Terlipressin plus NE and dobutamine   NE                       ICU mortality                                       3

  [@B35] [^a^](#fnT1_1){ref-type="table-fn"}   Single center   45                Septic shock                           Terlipressin plus NE\                                      NE                       ICU mortality                                       3
                                                                                                                        AVP plus NE                                                                                                                             

  [@B37]^\*^                                   Single center   387               Septic shock                           Vasopressin plus NE                                        NE                       28-day mortality                                    3

  [@B38]^\*^                                   Single center   184               Cirrhosis with septic shock.           Terlipressin plus NE                                       NE                       30-day mortality                                    1

  [@B41]                                       Multicenter     799               Septic shock                           Vasopressin                                                NE                       28-day mortality 90-day mortality                   5

  [@B42]                                       Multicenter     48                Septic shock                           Selepressin                                                Placebo                  28-day mortality                                    5

  [@B50]                                       Single center   30                Septic shock                           Terlipressin plus NE                                       NE                       28-day mortality                                    3

  [@B54]                                       Single center   32                Septic shock                           Terlipressin plus NE                                       NE                       7-day mortality 24-h mortality                      3

  [@B55]^\*^                                   Single center   107               Septic shock and cancer                Vasopressin                                                NE                       28-day mortality                                    1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NE, norepinephrine; AVP, arginine vasopressin; ICU, intensive care unit; ARDS, acute respiratory distress syndrome.

NA, not available from article or author.

\*Published in abstract only.

[@B34] and [@B35] have compared three arms.

Risk of Bias Assessment {#s3_2}
-----------------------

Each RCT in our study was assigned a score of 0 to 5 by using Jadad scoring system ([**Supplemental Table S1**](#SM9){ref-type="supplementary-material"}). The majority of enrolled trials met the randomization requirements by using distribution methods. Among them, 8 RCTs (34.8%) had Jadad score of 4 or 5, while eight studies (34.8%) scored 3, indicating that 16 included RCTs (69.6%) were of low risk of bias. While seven studies (30.4%) were given Jadad score of 1 or 2, indicating a high risk of bias that was mainly due to the publication types and lack of blinding.

Primary Outcome: 28-Day or 30-Day Mortality {#s3_3}
-------------------------------------------

Mortality data were accessible in 23 trials, 17 of them have reported 28-day or 30-day mortality, while six studies reported other endpoints. Pooled data form 23 trials demonstrated no significant reduction in 28-day or 30-day mortality among patients who were given vasopressin or its analogs when comparing to those using catecholamines alone \[RR=0.94 (95% CI, 0.87--1.01), *P*=0.08, I^2^ = 0%\]. The forest plot was shown in [**Figure 2**](#f2){ref-type="fig"}.

![Forest plot of 28-day or 30-day mortality comparing vasopressin or its analogs to catecholamines alone among septic shock patients. VP, vasopressin; RR, risk ratio; CI, confidence intervals.](fphar-11-00563-g002){#f2}

As summarized in [**Table 2**](#T2){ref-type="table"}, the consequence remained unchanged when conducting sensitivity analysis. As stratifying by interventions, RR of the vasopressin group was 0.96 \[(95% CI, 0.87--1.06), *P*=0.44, I^2^ = 0%\]. For studies incorporated septic shock patients without other primary complications, the combined RR was 0.94 \[(95% CI, 0.87--1.03), *P*=0.20, I^2^ = 0%\]. After removing trials reported mortality in other phases, there was no significant difference between two groups \[RR=0.95 (95% CI, 0.88--1.02), *P*=0.18, I^2^ = 0%\]. Besides, combined RR of pooling data from studies with low risk of bias was 0.95 \[(95% CI, 0.88--1.03), *P*=0.22, I^2^ = 0%\]. Of note, combined RR for studies published in full text and abstract were 0.95 \[(95% CI, 0.87--1.04), *P*=0.30, I^2^ = 0%\], and 0.90 \[(95% CI, 0.79--1.02), *P*=0.09, I^2^ = 55%\], respectively.

###### 

Subgroup analysis and sensitivity analyses on primary outcome.

  Subgroup                  No. of studies                    No. of patients   RR (95% CI)   I^2^                *P* value   
  ------------------------- --------------------------------- ----------------- ------------- ------------------- ----------- ------
  **Intervention**                                                                                                            
                            Vasopressin                       10                2,147         0.96 (0.87--1.06)   0%          0.44
                            Analogs                           13                2,093         0.91 (0.82--1.01)   3%          0.07
  **Clinical setting**                                                                                                        
                            Septic shock only                 16                3,487         0.94 (0.87--1.03)   0%          0.20
                            Septic shock with complications   7                 738           0.91 (0.80--1.03)   40%         0.15
  **Outcome measurement**                                                                                                     
                            28-day or 30-day mortality        17                4,022         0.95 (0.88--1.02)   0%          0.18
                            ICU mortality                     4                 151           0.82 (0.63--1.07)   2%          0.15
  **Risk of bias**                                                                                                            
                            Low risk                          16                3,637         0.95 (0.88--1.03)   0%          0.22
                            High risk                         7                 588           0.87 (0.74--1.02)   29%         0.09
  **Publication type**                                                                                                        
                            Full text                         17                3,191         0.95 (0.87--1.04)   0%          0.30
                            Abstract                          6                 1,034         0.90 (0.79--1.02)   55%         0.09

ICU, intensive care unit; RR, risk ratio; CI, confidence interval.

Meanwhile, we performed a subgroup analysis based on disparate administration of vasoactive agents. As no statistical significances were observed in both vasopressin and selepressin subgroups, we found a significant lower 28-day or 30-day mortality rate among septic shock patients who received terlipressin \[RR=0.87 (95% CI, 0.77--0.98), *P*=0.02, I^2^ = 12%\] ([**Figure 3**](#f3){ref-type="fig"}).

![Forest plot of 28-day or 30-day mortality comparing vasopressin or its analogs to catecholamines alone stratified by disparate vasopressors. VP, vasopressin; RR, risk ratio; CI, confidence intervals.](fphar-11-00563-g003){#f3}

Secondary Outcomes {#s3_4}
------------------

### Total Adverse Events {#s3_4_1}

Given that 14 trials with a total of 3,206 patients reported total adverse events (980 events) ([@B27]; [@B41]; [@B35]; [@B13]; [@B55]; [@B5]; [@B9]; [@B15]; [@B54]; [@B8]; [@B38]; [@B42]; [@B30]; [@B26]), administration of vasopressin or its analogs showed no significant association with the incidence of adverse effects \[RR=1.21 (95% CI, 0.88--1.68), *P*=0.24, I^2^ = 73%\] ([**Supplemental Figure S1**](#SM1){ref-type="supplementary-material"}). Although this outcome displayed a relatively high heterogeneity, the conclusion was proven to be stable after performing sensitivity analysis *via* excluding each study one at a time from the pooled estimate. Meanwhile, we found that study by Liu et al. was the main source of heterogeneity, which resulted in remarkable reduction in heterogeneity after exclusion (I^2^ from 73% to 41%).

### Arrhythmia {#s3_4_2}

The development of arrhythmia was documented in nine RCTs with 358 events ([@B41]; [@B35]; [@B5]; [@B9]; [@B15]; [@B8]; [@B42]; [@B30]; [@B26]). We observed no significant difference in the occurrence of arrhythmia between two groups \[RR=1.05 (95% CI, 0.87--1.27), *P*=0.61, I^2^ = 25%\] ([**Supplemental Figure S2**](#SM2){ref-type="supplementary-material"}). Of note, trials by Laterre and colleagues accounted for over 76.4% weight. Even so, the conclusion was not altered after removing this study.

### Digital Ischemia {#s3_4_3}

By pooling data from nine studies with 2,929 participants (a total of 105 events) ([@B41]; [@B50]; [@B13]; [@B5]; [@B15]; [@B6]; [@B42]; [@B30]; [@B26]), we demonstrated that vasopressin or its analogs could lead to approximately two times risk of digital ischemia when compared to sole use of catecholamine in septic shock patients \[RR=2.65 (95% CI, 1.26--5.56), *P* \< 0.01, I^2^ = 48%\] ([**Figure 4**](#f4){ref-type="fig"}). We further confirmed that the result was robust through implementing sensitivity analysis, and excluding trial by Liu et al. could completely eliminate the heterogeneity (I^2^=0%).

![Forest plot of digital ischemia comparing vasopressin or its analogs to catecholamines alone among septic shock patients. VP, vasopressin; RR, risk ratio; CI, confidence interval.](fphar-11-00563-g004){#f4}

### ICU Length of Stay {#s3_4_4}

Twelve included RCTs with 3,203 patients were eligible for the analysis of ICU length of stay ([@B34]; [@B41]; [@B35]; [@B18]; [@B23]; [@B5]; [@B15]; [@B6]; [@B7]; [@B8]; [@B30]; [@B26]). Pooled effects revealed that administration of vasopressin or its analogs did not impact the length of stay in ICU \[MD=--0.21 (95% CI, −0.75--0.33), *P* =0.44, I^2^ = 0%\] ([**Supplemental Figure S3**](#SM3){ref-type="supplementary-material"}).

AMI and Cardiac Arrest, Acute Mesenteric Ischemia, Hospital Length of Stay and MV Duration {#s3_5}
------------------------------------------------------------------------------------------

The occurrence of AMI and cardiac arrest, acute mesenteric ischemia, and hospital length of stay as well as MV duration were reported in 7, 5, 6, 6 studies, respectively. None of those outcomes showed significant differences between two groups ([**Supplemental Figure S4**](#SM4){ref-type="supplementary-material"}**--**[**S7**](#SM7){ref-type="supplementary-material"}). Accordingly, the pooled effects and detailed information for those outcomes were presented in [**Table 3**](#T3){ref-type="table"}.

###### 

Summary of primary and secondary outcomes.

  Outcome                  No. of events/No. of total patients   RR (95%CI)   MD (95%CI)   I^2^                *P* value             Quality of evidence[^a^](#fnT3_1){ref-type="table-fn"}            
  ------------------------ ------------------------------------- ------------ ------------ ------------------- --------------------- -------------------------------------------------------- -------- -----------------------------------
  **Primary endpoint**                                                                                                                                                                                 
                           28-day or 30-day mortality            891/2,277    829/1,948    0.94 (0.87--1.01)                         0%                                                       0.08     Moderate (Inconsistency)
  **Secondary endpoint**                                                                                                                                                                               
                           Total adverse effects                 639/1,766    341/1,440    1.21 (0.88--1.68)                         73%                                                      0.24     Low (Inconsistency, Risk of bias)
                           Arrhythmia                            237/1,580    121/1,250    1.05 (0.87--1.27)                         25%                                                      0.61     Moderate (Inconsistency)
                           AMI and cardiac arrest                69/1,480     43/1,162     1.05 (0.72--1.54)                         0%                                                       0.79     Moderate (Imprecision)
                           Digital ischemia                      84/1,619     21/1,310     2.65 (1.26--5.56)                         48%                                                      \<0.01   Moderate (Inconsistency)
                           Acute mesenteric ischemia             37/1,452     27/1,137     0.99 (0.60--1.63)                         0%                                                       0.96     Moderate (Inconsistency)
                           ICU length of stay                                                                  −0.21 (−0.75--0.33)   0%                                                       0.44     Low (Inconsistency, Indirectness)
                           Hospital length of stay                                                             0.15 (−1.39--1.70)    0%                                                       0.85     Low (Inconsistency, Indirectness)
                           MV duration                                                                         −0.47 (−1.18--0.24)   46%                                                      0.19     Low (Indirectness, Imprecision)

ICU, intensive care unit; MV, mechanical ventilation; RR, risk ratio; MD, mean difference; CI, confidence interval.

Quality of evidence of each outcome was assessed by using GRADE method.

Quality of Evidence {#s3_6}
-------------------

The results of GRADE evaluation for all outcomes were summarized in [**Table 3**](#T3){ref-type="table"} and [**Supplemental Table S2**](#SM10){ref-type="supplementary-material"}. The quality of evidence for the primary endpoint and several secondary outcomes were ranked as moderate, including arrhythmia, AMI and cardiac arrest, digital ischemia, and acute mesenteric ischemia. Whereas, total adverse effects, hospital/ICU lengths of stay as well as MV duration were assessed as outcomes with low quality of evidence.

Publication Bias {#s3_7}
----------------

Publication bias was evaluated through visually inspecting the funnel plot, which revealed no evidence of publication bias. Furthermore, we applied Harbord test (*P*=0.47), and Peters test (*P*=0.25) to validate the funnel plot symmetry, which were both noted with no statistical significance ([**Supplemental Figure S8**](#SM8){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In the current systematic review and meta-analysis, we have evaluated the clinical efficiency of vasopressin or its analogs among patients with septic shock. We found that administration of vasopressin or selective V~1~ receptor agonists showed no benefits in reducing 28-day or 30-day mortality when compared with solely using NE, which was further validated by sensitivity analysis. Intriguingly, terlipressin might have potential prosurvival effects on septic shock patients independent of NE administration, as reported in subgroup analysis. Further large RCTs were required to strengthen the clinical efficiency of terlipressin among patients with septic shock. Meanwhile, no significant differences were observed in the incidence of most adverse effects between two groups, including total adverse events, arrhythmia, AMI and cardiac arrest, acute mesenteric ischemia. Of note, the occurrence of digital ischemia was more frequent among patients who received vasopressin or its analogs than those solely using catecholamines. Additionally, there were no significant improvements on ICU or hospital length of stay, as well as MV duration after administration of vasopressin or its analogs.

NE has long been recommended as the first-line vasoactive agent among patients with septic shock ([@B40]), and was broadly applied in restoring blood perfusion in tissue and vital organs and enhancing efficacy of fluid resuscitation ([@B4]; [@B20]; [@B40]). However, high dose of NE reportedly caused severe side-effects, such as myocardial injury and immunological dysfunction, which made its long-lasting usage impossible ([@B3]; [@B52]). Vasopressin, an alternative non-catecholamine agent, was capable of increasing vascular resistance and restoring blood pressure *via* promoting arterioles constriction, which was also in favor of reducing the requirement of catecholamines among septic shock patients ([@B12]; [@B21]; [@B32]; [@B52]). Meanwhile, it has been manifested that vasopressin could promote water resorption in renal tubules through its affinity to V~2~ receptors, thereby maintaining circulation blood volume ([@B52]). Given that, recently issued Surviving Sepsis Guidelines has recommended adding vasopressin as the second-line vasoactive agent for the treatment of septic shock patients ([@B40]). Up to now, the Vasopressin or Septic Shock Trial (VASST) that was carried out by Russell and colleagues was the largest RCT for addressing this topic ([@B41]). However, they failed to reveal a reduced 28-day mortality among septic shock patients receiving NE combined with low-dose vasopressin (0.01 to 0.03 U/min) compared to those with sole use of NE, while a higher survival rate for vasopressin plus NE group was observed merely in the subset of patients with less severe septic shock ([@B41]). Meanwhile, other researchers have reported that administration of vasopressin in relatively late phases (after 12 h) and at high lactate levels might result in low response to vasopressin ([@B45]). Additionally, growing evidences also suggested that vasopressin might be associated with decreased urine and cardiac outputs, as well as prothrombotic state due to its nonselective effects on V~1~ and V~2~ receptors ([@B51]; [@B46]; [@B56]). Therefore, the effects and safety of vasopressin should be taken cautiously.

In the current meta-analysis, we found that the use of vasopressin or its analogs had no effect on reducing 28-day or 30-day mortality among patients with septic shock. Whereas, it was disparate from many previous published systematic review and meta-analyses ([@B32]; [@B24]). A recent study by Jiang et al. has concluded that the use of vasopressin might lead to reduced mortality among patients with septic shock ([@B24]). Although the study was well-performed and comprehensive, some flaws might interfere the interpretation of their findings. They incorporated Malay's study in the analysis of 28-day or 30-day mortality, but that study merely reported 24-h mortality, which might render an unsolvable bias. Besides, they failed to conduct sensitivity analysis for primary endpoint which was clearly unstable. Neto et al. performed a systematic review and meta-analysis by enrolling nine RCTs and demonstrated a reduced all-cause mortality in patients with vasodilatory shock, which showed statistical significance in septic shock subgroup ([@B48]). Of note, an updated study by McIntyre et al. showed that vasopressin in addition to catecholamines was associated lower mortality rate and incidence of atrial fibrillation among patients with distributive shock ([@B32]). The reason for the divergent results was mainly due to stricter inclusion criteria and incorporation of newly published RCTs. However, the current meta-analysis initially revealed a reduced 28-day or 30-day mortality among patients receiving terlipressin compared to those with catecholamines alone, which haven't been reported by any other existing systematic review and meta-analyses.

Terlipressin, which is a synthetic long-acting analog of vasopressin, has high affinity toward V~1~ receptors on vascular smooth muscle ([@B28]). Theoretically, the use of terlipressin may result in less adverse effects than vasopressin does in treating septic shock, including thrombocytopenia, decreased cardiac output and hyponatremia ([@B39]; [@B46]). Indeed, several pre-clinical studies have demonstrated that administration of terlipressin could reduce the requirement of NE, restore hemodynamic status and promote creatinine clearance among septic shock patients ([@B34]; [@B35]; [@B30]). Previous studies reported that terlipressin could improve renal function in patients diagnosed with hepatorenal syndrome, two trials further identified a reduced 28-day or 30-day mortality among septi shock patients complicated with liver cirrhosis after administration of terlipressin. Their findings were in accordance with the results of our analysis ([@B8]; [@B38]). However, study by Zhu et al. didn't reveal any pro-survival benefits of terlipressin among septic shock patients compared with sole administration of catecholamines ([@B56]). They enrolled a total of 10 studies in their analysis, but one trial was conducted in pediatric ICU, which was largely disparate from other included trials and might potentially introduce bias. Besides, study by Liu et al. took over more than half of the total sample size, which might lead to significant publication bias and impaired robustness.

Selepressin is a novel vasopressin analog, which selectively stimulates V~1a~ receptors ([@B25]; [@B42]). As demonstrated in pre-clinical studies, selepressin was capable of reducing fluid requirements and attenuating edema ([@B31]; [@B19]; [@B44]). In a recently published phase 2b/3 trial in septic shock patients, researchers didn't find any favorable improvements in vasopressor- and ventilator-free days as well as 30-day mortality after administration of selepressin ([@B26]).

As for secondary endpoints of interest, we found that the incidence of digital ischemia was significantly higher in patients receiving vasopressin or its analogs when compared to those solely using catecholamines. This finding was in line with many other systematic review and meta-analyses, which could be partially explained by vasopressin related cardiac output reduction and prothrombotic state. Meanwhile, we did not reveal any statistical differences between two groups in analysis of remaining secondary outcomes, including total adverse events, arrhythmia, AMI and cardiac arrest, acute mesenteric ischemia, ICU/hospital length of stay, and MV duration.

Several limitations should be taken into consideration when interpreting our findings. Firstly, the reported endpoints varied across included studies. Although the majority of trials provided 28-day or 30-day mortality, there were still a few studies that only presented data on ICU mortality, hospital mortality or 7-day mortality. However, we enrolled survival data of all included trials in the analysis of primary outcomes, which might potentially introduce bias. Given that, we performed sensitivity analysis and excluded studies that reported mortality in other phases. Correspondingly, the conclusions remained unchanged. Secondly, heterogeneity of some secondary endpoints was relatively high. We further conducted sensitivity analyses in order to unravel the source of heterogeneity. Thirdly, as the timing, duration, precise dose, delivery methods as well as weaning of vasopressin or its analogs were disparate and uncontrollable among included trials, it might render bias and affect the robustness of our conclusions. However, the detailed information was insufficient in many trials, which restricted us from performing further subgroup analyses. Finally, we failed to compare the clinical efficacy between vasopressin and its analogs. Thus, network meta-analyses were required to address this issue in the future.

Conclusions {#s5}
===========

In this study, administration of vasopressin or its analogs showed no significant improvement in reducing 28-day or 30-day mortality among patients with septic shock when compared with those solely using catecholamines, while administration of terlipressin might be benefit for survival of septic shock patients comparing to catecholamines alone. Besides, septic shock patients receiving vasopressin or its analogs did present an increased risk of digital ischemia in comparison with those solely using catecholamines.
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